Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Bilêl Habacha"'
Autor:
Rudolf A. Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Takahiro Higuchi, Philipp Hartrampf, Sebastian E. Serfling, Thorsten Derlin, Constantin Lapa, Andreas K. Buck, Markus Essler, Kenneth J. Pienta, Mario A. Eisenberger, Mark C. Markowski, Laura Shinehouse, Rehab AbdAllah, Ali Salavati, Martin A. Lodge, Martin G. Pomper, Michael A. Gorin, Ralph A. Bundschuh, Steven P. Rowe
Publikováno v:
Molecular Imaging, Vol 2022 (2022)
Objectives. In patients with prostate cancer (PC) receiving prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT), higher baseline standardized uptake values (SUVs) are linked to improved outcome. Thus, readers deciding on RL
Externí odkaz:
https://doaj.org/article/5bfc1256bc1347abb2e5c98b1daffdae
Autor:
Rudolf A. Werner, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K. Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A. Lodge, Kenneth J. Pienta, Mario A. Eisenberger, Mark C. Markowski, Michael A. Gorin, Martin G. Pomper, Steven P. Rowe, Ralph A. Bundschuh
Publikováno v:
The Prostate.
Objectives We evaluated 18F-DCFPyL test–retest repeatability of uptake in normal organs. Methods Twenty-two prostate cancer (PC) patients underwent two 18F-DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b554bce88166ce3d0431c4dd27bf0c04
https://doi.org/10.1002/pros.24577
https://doi.org/10.1002/pros.24577
Autor:
Rudolf A. Werner, Bilêl Habacha, Susanne Lütje, Lena Bundschuh, Alekandser Kosmala, Markus Essler, Thorsten Derlin, Takahiro Higuchi, Constantin Lapa, Andreas K. Buck, Kenneth J. Pienta, Martin A. Lodge, Mario A. Eisenberger, Mark C. Markowski, Martin G. Pomper, Michael A. Gorin, Eric C. Frey, Steven P. Rowe, Ralph A. Bundschuh
Objectives PET-based radiomic metrics are increasingly utilized as predictive image biomarkers. However, the repeatability of radiomic features on PET has not been assessed in a test–retest setting. The prostate-specific membrane antigen-targeted c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07dff257b52dc6aa6f48dd1f55e6c219
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/104739
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/104739
Autor:
Rudolf A, Werner, Bilêl, Habacha, Susanne, Lütje, Lena, Bundschuh, Takahiro, Higuchi, Philipp, Hartrampf, Sebastian E, Serfling, Thorsten, Derlin, Constantin, Lapa, Andreas K, Buck, Markus, Essler, Kenneth J, Pienta, Mario A, Eisenberger, Mark C, Markowski, Laura, Shinehouse, Rehab, AbdAllah, Ali, Salavati, Martin A, Lodge, Martin G, Pomper, Michael A, Gorin, Ralph A, Bundschuh, Steven P, Rowe
Publikováno v:
Molecular imaging. 2022
In patients with prostate cancer (PC) receiving prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT), higher baseline standardized uptake values (SUVs) are linked to improved outcome. Thus, readers deciding on RLT must have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e7be7659a1279529e0b2c0f9cf8d480b
https://pubmed.ncbi.nlm.nih.gov/35283693
https://pubmed.ncbi.nlm.nih.gov/35283693